Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/07
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 06/30/16
End: 01/31/22
Due: 01/31/23
Phase: N/A
Priority: Normal
Start: 02/28/13
End: 02/28/18
Due: 02/28/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | NCT00672295 | AA Secord | user2@example.com | None | 2007-08-31 | 2012-11-30 | 2013-11-30 | - | - | 2025-07-14 |
| A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | NCT02728830 | AA Secord | user2@example.com | None | 2016-06-30 | 2022-01-31 | 2023-01-31 | - | - | 2025-07-14 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | NCT01669798 | AA Secord | user2@example.com | None | 2013-02-28 | 2018-02-28 | 2019-02-28 | - | - | 2025-07-14 |